Amgen Inc. (NASDAQ:AMGN) is seeing shares trade up another 2% pre-market after yesterday's decision where an FDA panel rejected a proposal to set a specific target for red blood-cell levels ... Read Full Story »
Amgen (NASDAQ:AMGN) has a huge day ahead of it. The biotech giant is presenting data today on the appropriateuse of Erythropoiesis Stimulating Agents in Chronic RenalFailure patients to a joint ... Read Full Story »